Analysis of epithelial-cadherin and human epidermal growth factor receptor 2/ expression in gastric carcinoma using immunohistochemistry

Dewan, Khushboo; Madan, Renu; Sengupta, Prasanta; Bharadwaj, Reena

doi:10.4103/0377-4929.155303

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies 6,9,10 show the prevalence of E-cadherin aberrancy as 11-52% of gastric adenocarcinoma. In contrast to another study from India by Dewan K et al 13 , the present study shows a higher rate of E-cadherin aberrancy. This could be explained by the fact that the present study included both heterogeneous and negative E-cadherin staining as aberrant while only negative E-cadherin staining was considered abnormal in the earlier mentioned study.…”

Section: Discussioncontrasting

confidence: 99%

E-cadherin Immunohistochemical Expression in Gastric Carcinoma

Sadanandan¹,

Arunraj²

2020

IJCMR

View full text Add to dashboard Cite

Introduction: Carcinoma of the stomach is a disease with a grave prognosis. The revelation of the genetic and molecular basis of gastric cancer has helped the development of targeted therapies which has the potential to improve survival. Decreased expression of Epithelial cadherin (E-cadherin) in gastric carcinoma is one such genetic alteration which could help in targeted therapy and prognostication. The objective of the present study was to identify E-cadherin immunohistochemical expression in gastric carcinoma and its correlation with histopathological features. Material and Methods: Gastric biopsies and surgical specimens from a tertiary care center in South India were included and assessed by light microscopy and immunohistochemistry (IHC). Results: Aberrant E-cadherin staining was seen in 42.8% of gastric adenocarcinoma. Aberrant staining was found with disproportionately high frequency in diffuse-type (95.5%) when compared to intestinal-type (18.6%) and mixed type (20%) with very high statistical significance with P <0.001. All (100%) poorly differentiated tumors had aberrant E-cadherin staining while only 21.2% of moderately differentiated and 12.5% of well-differentiated tumors had aberrant E-cadherin staining and this was statistically highly significant with P <0.001. In this study, there was no significant association between E-cadherin with age, gender, nature of the specimen, site of the tumor, size of the tumor, lymph node status and tumor invasion. Conclusion: This study emphasizes the importance of identification of aberrant E-cadherin expression in gastric carcinomas which in turn helps in selecting patients for novel therapies which might improve the prognosis of this grave disease.

show abstract

Section: Discussioncontrasting

confidence: 99%

E-cadherin Immunohistochemical Expression in Gastric Carcinoma

Sadanandan¹,

Arunraj²

2020

IJCMR

View full text Add to dashboard Cite

show abstract

“…22,23,24,10,25,26 In our study, the expression of HER-2/neu is 21.17 %. In a similar study in India by Dewan et al 27 from Army Hospital Research and Referral Centre, Delhi Cantt, the prevalence of HER-2/neu expression was 17.0%. So our results are almost comparable with this study.…”

Section: Discussionmentioning

confidence: 72%

“…This evaluation of HER-2/neu gene amplification by FISH is important because only those cases that are grade 3+ and 2+ by immunohistochemistry, that are positive for FISH amplification present evidence of more benefit of adding trastuzumab to the chemotherapy regimen. 28,24,6,27 With advent of molecular targeted therapy, we need to determine HER-2/neu expression accurately in order to determine which patients are going to benefit from this drug.…”

Section: Discussionmentioning

confidence: 99%

Her-2/Neu Expression in Stomach and Gastro-Oesophageal Junction Carcinoma in Endoscopic Biopsy Specimens

Atri¹,

Rana²,

Chandial³

2017

jemds

View full text Add to dashboard Cite

BACKGROUNDPrognosis of patients with advanced inoperable carcinoma of stomach and gastro-oesophageal junction remains dismal with palliative chemotherapy. In spite of extensive efforts, the five-year survival rate of these patients worldwide is 20%. The main problem with chemotherapy is its toxicity and thus the management of these patients is very complex. These patients also have associated comorbidities. Therefore, there is a need to understand the molecular biology of these malignancies and develop personalised, specialised and molecular targeted therapy. Hence, we planned this study to evaluate the expression of HER-2/neu in carcinoma of stomach and gastro-oesophageal junction. MATERIALS AND METHODSThis was an observational study from January 2010 to December 2016 wherein all cases of carcinoma of stomach and gastrooesophageal junction were retrieved and reviewed. Immunohistochemistry for HER-2/neu protein was done. Statistical analysis was done using SPSS 10.0 windows student version {SPSS Inc., 233 South Wacker Drive, 11 th Floor, Chicago, IL 60606-6412}. RESULTSThe age of patients varied from 34 to 72 years and mean age was 58.5 years. The common clinical presentation was dyspepsia and regurgitation (82.4%). Of total 85 cases, the grade of HER-2/neu expression was as follows: 0 in 65 (76.47 %) cases, 1+ in 2 (2.3%) cases, 2+ (equivocal) in 4 (4.70 %) cases and 3+ in 14 (16.47 %) cases. CONCLUSIONAssessment of HER-2/neu gene amplification by FISH technique and HER-2/neu protein overexpression by immunohistochemistry should be done in all patients with gastric and gastro-oesophageal carcinoma especially inoperable cases so that these patients are treated with molecularly targeted therapy.

show abstract

E-Cadherin Expression in Gastric Adenocarcinoma

C¹,

K²,

Sankar³

2018

jemds

View full text Add to dashboard Cite

BACKGROUND Gastric adenocarcinoma is one of the most common cancers in the world and 2nd most common cause of cancer deaths. It develops due to genetic and environmental factors. Histologically, Lauren's classified Gastric adenocarcinoma is classified into intestinal and diffuse types. Intestinal type can be of well differentiated, moderately differentiated or poorly differentiated. E-cadherin is a protein that helps in cell to cell adhesion. This study is conducted to find out relation between E-cadherin expression and tumour infiltration and lymph node status. MATERIALS AND METHODS A descriptive study was conducted to assess E-cadherin expression in gastric adenocarcinoma specimens received in the Department of Pathology, Govt. Medical College, Kottayam during a period of 15 months (March 2016-June 2017). RESULTS Among 46 cases studied, 40 (80%) cases showed aberrant/ loss of E-cadherin expression. Among these 16 (72%) cases were well differentiated type, 5 (100%) cases were moderately differentiated, 2 (100%) cases were poorly differentiated and 17 (100%) cases were diffuse type. Aberrant/ loss of expression is seen in 29 (87%) cases of lymph node positivity. Aberrant/ loss of expression is seen in 37 (88%) cases of T3/T4 stage. CONCLUSION In the study aberrant E-cadherin expression was seen in 74% cases, loss of expression in 13% cases and normal expression in 13% cases. A negative correlation was seen between E-cadherin expression and lymph node status. Level of tumour invasion also had a negative correlation with E-cadherin expression.

show abstract

Analysis of epithelial-cadherin and human epidermal growth factor receptor 2/ expression in gastric carcinoma using immunohistochemistry

Cited by 3 publications

References 0 publications

E-cadherin Immunohistochemical Expression in Gastric Carcinoma

E-cadherin Immunohistochemical Expression in Gastric Carcinoma

Her-2/Neu Expression in Stomach and Gastro-Oesophageal Junction Carcinoma in Endoscopic Biopsy Specimens

E-Cadherin Expression in Gastric Adenocarcinoma

Contact Info

Product

Resources

About